Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Int J Environ Res Public Health. 2022 Dec 30;20(1):646. doi: 10.3390/ijerph20010646.
(1) Background: Respiratory co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other viruses are common, but data on clinical outcomes and laboratory biomarkers indicative of disease severity are limited. We aimed to compare clinical outcomes and laboratory biomarkers of patients with SARS-CoV-2 alone to those of patients with SARS-CoV-2 and either rhinovirus or adenovirus. (2) Methods: Hospitalized patients co-infected with SARS-CoV-2 and rhinovirus and patients co-infected with SARS-CoV-2 and adenovirus were matched to patients infected with SARS-CoV-2 alone. Outcomes of interest were the cumulative incidences of mechanical ventilation use, intensive care unit (ICU) admission, 30-day all-cause mortality, and 30-day all-cause readmission from the day of discharge. We also assessed differences in laboratory biomarkers from the day of specimen collection. (3) Results: Patients co-infected with SARS-CoV-2 and rhinovirus, compared with patients infected with SARS-CoV-2, had significantly greater 30-day all-cause mortality (8/23 (34.8%) vs. 8/69 (11.6%), = 0.02). Additionally, median alanine transaminase (13 IU/L vs. 24 IU/L, = 0.03), aspartate transaminase (25 IU/L vs. 36 IU/L, = 0.04), and C-reactive protein (34.86 mg/L vs. 94.68 mg/L, = 0.02) on day of specimen collection were significantly lower in patients co-infected with SARS-CoV-2 and rhinovirus in comparison to patients infected with SARS-CoV-2 alone. Clinical outcomes and laboratory markers did not differ significantly between patients with SARS-CoV-2 and adenovirus co-infection and patients with SARS-CoV-2 mono-infection. (4) Conclusion: SARS-CoV-2 and rhinovirus co-infection, compared with SARS-CoV-2 mono-infection alone, is positively associated with 30-day all-cause mortality among hospitalized patients. However, our lack of significant findings in our analysis of patients with SARS-CoV-2 and adenovirus co-infection may suggest that SARS-CoV-2 co-infections have variable significance, and further study is warranted.
(1)背景:严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)与其他病毒的呼吸道合并感染很常见,但有关临床结局和提示疾病严重程度的实验室生物标志物的数据有限。我们旨在比较单独感染 SARS-CoV-2 的患者与同时感染 SARS-CoV-2 及鼻病毒或腺病毒的患者的临床结局和实验室生物标志物。
(2)方法:将 SARS-CoV-2 与鼻病毒合并感染的住院患者和 SARS-CoV-2 与腺病毒合并感染的患者与单独感染 SARS-CoV-2 的患者相匹配。感兴趣的结局是机械通气使用率、入住重症监护病房(ICU)、30 天全因死亡率和从出院日起 30 天全因再入院的累积发生率。我们还评估了从标本采集日起实验室生物标志物的差异。
(3)结果:与单独感染 SARS-CoV-2 的患者相比,同时感染 SARS-CoV-2 和鼻病毒的患者 30 天全因死亡率显著更高(8/23 [34.8%] vs. 8/69 [11.6%], = 0.02)。此外,同时感染 SARS-CoV-2 和鼻病毒的患者在标本采集日的中位丙氨酸转氨酶(13 IU/L vs. 24 IU/L, = 0.03)、天冬氨酸转氨酶(25 IU/L vs. 36 IU/L, = 0.04)和 C 反应蛋白(34.86 mg/L vs. 94.68 mg/L, = 0.02)明显更低。与单独感染 SARS-CoV-2 的患者相比,同时感染 SARS-CoV-2 和腺病毒的患者的临床结局和实验室标志物无显著差异。
(4)结论:与单独感染 SARS-CoV-2 相比,SARS-CoV-2 和鼻病毒合并感染与住院患者 30 天全因死亡率呈正相关。然而,我们在分析 SARS-CoV-2 和腺病毒合并感染患者时未发现显著差异,这可能表明 SARS-CoV-2 合并感染的意义不同,需要进一步研究。